Fluorophenylalanine Dipeptides (S,S)-4-F-Phe-Ala and (S,S)-3,4-diF-Phe-Ala Inhibit *P. aeruginosa* Biofilm
Background
The global health crisis of antibiotic resistance urgently demands novel antibacterial strategies. Pseudomonas aeruginosa is a major opportunistic pathogen known for forming persistent, device-associated biofilms, which significantly complicate clinical management and treatment. Current antibiotics often struggle to penetrate and eradicate these protective bacterial communities. Antimicrobial peptides (AMPs) offer a promising alternative due to their broad-spectrum activity and lower propensity for resistance development, making them attractive candidates for developing new therapeutics against biofilm-related infections.
Study Design
Researchers synthesized over 100 dipeptides containing fluorinated phenylalanine (F-Phe) residues. These compounds were evaluated against Pseudomonas aeruginosa in a primary biofilm formation assay. Further study focused on two lead compounds: (S,S)-4-F-Phe-Ala and (S,S)-3,4-diF-Phe-Ala. The study assessed their ability to inhibit bacterial growth and biofilm formation. Additionally, mammalian cell lines were treated with both dipeptides at high concentrations to evaluate their selective toxicity, ensuring potential therapeutic safety margins.
Results
Several novel F-Phe dipeptides were identified that significantly inhibited P. aeruginosa biofilm formation at concentrations of 1 μg/mL or less. Detailed analysis of two lead compounds revealed distinct biological profiles. Inhibition of biofilm formation by (S,S)-4-F-Phe-Ala was directly correlated with its ability to inhibit bacterial growth. In contrast, (S,S)-3,4-diF-Phe-Ala demonstrated a unique mechanism: it effectively inhibited biofilm formation without significantly inhibiting bacterial growth at concentrations up to 100 μg/mL. This suggests a specific antibiofilm mechanism independent of bactericidal or bacteriostatic effects. Both dipeptides exhibited selective toxicity, as mammalian cell lines remained viable even when treated with much higher concentrations than those effective against P. aeruginosa. This indicates a promising therapeutic window.
(S,S)-3,4-diF-Phe-Ala inhibited P. aeruginosa biofilm formation without significant bacterial growth inhibition at concentrations up to 100 μg/mL, highlighting a novel antibiofilm mechanism.
Key Findings
- Over 100 fluorophenylalanine dipeptides were synthesized and screened for antibiofilm activity.
- Several dipeptides inhibited P. aeruginosa biofilm formation at concentrations of 1 μg/mL or less.
- (S,S)-4-F-Phe-Ala inhibited biofilm formation via bacterial growth inhibition.
- (S,S)-3,4-diF-Phe-Ala inhibited biofilm formation without significant growth inhibition up to 100 μg/mL.
- Both dipeptides showed selective toxicity for P. aeruginosa over mammalian cells.
Why It Matters
This discovery provides promising new leads for developing antibiofilm therapeutics, particularly against challenging pathogens like P. aeruginosa. The identification of (S,S)-3,4-diF-Phe-Ala, which inhibits biofilm formation independently of bacterial growth, is particularly significant. This mechanism could circumvent traditional antibiotic resistance pathways, offering a novel strategy to disarm bacterial infections without necessarily killing the bacteria, potentially reducing selective pressure for resistance. These dipeptides could form the basis for new drugs targeting chronic biofilm infections, where current treatments often fail. While currently in vitro, these findings pave the way for future in vivo studies and potential clinical translation, offering a new class of compounds for combination therapies or standalone treatments.
dipeptides
fluorophenylalanine
pseudomonas-aeruginosa
antibiofilm
antibacterial
antibiotic-resistance